Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

被引：31
|
作者：
LaCasce, Ann S. [1 ]
Bociek, R. Gregory [2 ]
Sawas, Ahmed [3 ]
Caimi, Paolo [4 ]
Agura, Edward [5 ]
Matous, Jeffrey [6 ]
Ansell, Stephen M. [7 ]
Crosswell, Howland E. [8 ]
Islas-Ohlmayer, Miguel [9 ]
Behler, Caroline [10 ]
Cheung, Eric [11 ]
Forero-Torres, Andres [12 ,13 ,15 ]
Vose, Julie [2 ]
O'Connor, Owen A. [3 ]
Josephson, Neil [13 ,15 ]
Wang, Yinghui [13 ]
Advani, Ranjana [14 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[5] Charles A Sammons Canc Ctr, Dallas, TX USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Mayo Clin, Rochester, MN USA
[8] St Francis Hosp, Greenville, SC USA
[9] Jewish Hosp Mercy Hlth, Cincinnati, OH USA
[10] Pacific Hematol Oncol Associates, San Francisco, CA USA
[11] Oncol Inst Hope & Innovat, Whittier, CA USA
[12] Univ Alabama Birmingham, Birmingham, AL USA
[13] Seattle Genet Inc, Bothell, WA USA
[14] Stanford Canc Inst, Stanford, CA USA
[15] Zymeworks Biopharmaceut Inc, Bothell, WA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期
关键词：
Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine; STEM-CELL TRANSPLANTATION; PHASE-II; CHEMOTHERAPY;
D O I：
10.1111/bjh.16499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E86 / E90
页数：5
相关论文
共 50 条
  • [1] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
    LaCasce, Ann S.
    Bociek, R. Gregory
    Sawas, Ahmed
    Caimi, Paolo
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen M.
    Crosswell, Howland E.
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Wang, Yinghui
    Advani, Ranjana
    BLOOD, 2018, 132 (01) : 40 - 48
  • [2] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
    Ulu, Bahar Uncu
    Dal, Mehmet Sinan
    Hindilerden, Ipek Yonal
    Akay, Olga Meltem
    Mehtap, Ozgur
    Buyukkurt, Nurhilal
    Hindilerden, Fehmi
    Gunes, Ahmet Kursad
    Yigenoglu, Tugce Nur
    Basci, Semih
    Cakar, Merih Kizil
    Acik, Didar Yanardag
    Korkmaz, Serdal
    Ulas, Turgay
    Ozet, Gulsum
    Ferhanoglu, Burhan
    Nalcaci, Meliha
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198
  • [3] BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    LaCasce, A.
    Bociek, G.
    Sawas, A.
    Caimi, P.
    Agura, E.
    Matous, J.
    Ansell, S.
    Crosswell, H.
    Islas-Ohlmayer, M.
    Behler, C.
    Cheung, E.
    Forero-Torres, A.
    Vose, J.
    O'Connor, O. A.
    Josephson, N.
    Advani, R.
    HAEMATOLOGICA, 2016, 101 : 45 - 46
  • [4] Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
    LaCasce, Ann S.
    Bociek, Gregory
    Sawas, Ahmed
    Caimi, Paolo F.
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen
    Crosswell, Howland
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Advani, Ranjana
    BLOOD, 2015, 126 (23)
  • [5] Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma
    Gulati, Nitya
    Boulad, Farid
    Cancio, Maria I.
    Curran, Kevin J.
    Jackson, Carolyn
    Kernan, Nancy
    Kung, Andrew L.
    O'Reilly, Richard
    Prockop, Susan
    Ramaswamy, Kavitha
    Scaradavou, Andromachi
    Spitzer, Barbara
    Shukla, Neerav
    Steinherz, Peter G.
    Forlenza, Christopher
    BLOOD, 2017, 130
  • [6] Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
    Picardi, M.
    Della Pepa, R.
    Giordano, C.
    Pugliese, N.
    Mortaruolo, C.
    Trastulli, F.
    Rascato, M. G.
    Cappuccio, I
    Raimondo, M.
    Memoli, M.
    Monteverde, M.
    Mascolo, M.
    Pane, F.
    BLOOD ADVANCES, 2019, 3 (09) : 1546 - 1552
  • [7] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [8] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
    Mei, Matthew
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Armenian, Saro
    Chen, Robert
    Rosen, Steven
    Forman, Stephen
    Popplewell, Leslie
    Kwak, Larry
    Martin, Peter
    Maddocks, Kami
    Bond, David
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
  • [9] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [10] Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis
    Abdelgawad, Hussien Ahmed H.
    Belal, Mohamed Mohamed
    Bashir, Mohamed Nabih
    Aboeldahab, Heba
    Eshun, Francis
    Otto, Mario
    Henry, Michael
    BLOOD, 2023, 142
12345